Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Thrombocytopenia 4Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Hodgkin Disease 2Solid Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioblastoma 1Chemotherapy-induced Thrombocytopenia 1

Interventions

fludarabine 6fludarabine phosphate 5Rituximab 5Cyclophosphamide 5Busulfan 4blinatumomab 3Lenalidomide 3thymoglobulin 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Bone Marrow Transplantation 2Biopsy 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2venetoclax 1sargramostim 1romiplostim 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1lirilumab 1ibrutinib 1duvelisib 1copanlisib 1Vincristine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphoid × romiplostim × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡